- Report ID: BMRC 1317 | Number of pages: 200 | Publish Date: Jan 2021
Status: Published | Category: Semiconductor | Delivery Timeline:
Brain Biomarker Market is valued at USD 12.92 Billion in 2020 and expected to reach USD 28.91 Billion by 2027 with the CAGR of 12.20% over the forecast period.
Brain Biomarker Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Increasing prevalence of neurological disorder and rising spend on research and development are some factors driving the brain biomarker market.
Biomarker is a characteristic which can be measured and evaluated as an indicator of a pathological as well as a physiological process or pharmacological response to a therapeutic intervention. In the era of molecular medicine, biomarkers usually mean molecular biomarkers and can be divided into 3 broad categories. The human brain is the most complicated organ in the body. The brain involves some common brain illnesses including stroke, motor neuron disease (MND), Alzheimer’s disease (AD) each of these conditions exhibit a unique pathology that enables clinicians to distinguish particular conditions and diagnosis and treatment. In this disease biomarker is utilized to monitor the for progression that can display a measurable degree of change over a timeframe. Biomarkers also used to measure the efficacy of a medicine that captures beneficial effect of the therapy. brain biomarker also used in clinical trials that enable the characterization of patient populations, quantify the extent to which new drugs reach intended targets and give access to indeed alter proposed disease mechanisms to achieve clinical outcomes for the disease treatment.
Brain biomarker is the procedure of changing the surface of an object, for the purpose of refining its appearance and durability. brain biomarker is related to electroplating, which is the production of a thin surface coating of the metal upon another by electro deposition. brain biomarker is an all-inclusive term used to describe the process of placing some type of metal covering on the surface of a metallic part, typically mentioned as a substrate. It can also comprise the implementation of a process for cleaning, polishing or improving a surface. brain biomarker often consists of electroplating, which is the process of putting metal ions onto a substrate via an electric current. In fact, brain biomarker and plating are sometimes used interchangeably. However, the brain biomarker business includes an extensive range of processes, each offering its own user benefits. Some common metal finishes include paint, lacquer, ceramic coatings, and other surface treatments. The brain biomarker industry usually categorizes plating operations as electroplating and electroless plating.
Brain biomarker market report is segmented based on type, application, end use and by regional & country level. Based upon type, brain biomarker market is classified into Genomic, Proteomic, Metabolomic, Imaging and Others. Based upon application, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders and Others. Based upon end use, brain biomarker market is classified into Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Other.
The regions covered in this brain biomarker market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of brain biomarker is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Brain biomarker market report covers prominent players like Qiagen N.V., Perkinelmer, Inc., Merck Millipore, Bio-Rad Laboratories, Inc., Enzo Biochem, Inc., EKF Diagnostics Holdings, Inc., LLC., Biosims Technologies Sas, Thermo Fisher Scientific, Cisbio Bioassays, Signosis Abbott Laboratories, Myriad RBM, Proteome Sciences, Athena Diagnostics, Immunarray Pvt. Ltd., Quanterix Corporation, Diagenic ASA, Psynova Neurotech, Meso Scale Diagnostics, and Bio-Rad Laboratories among others.
Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier
News: On January 26, 2017, Quanterix announced that it has entered into a definitive agreement to acquire UmanDiagnostics AB for USD22.5 million, that comprised of USD16 million in cash plus USD6.5 million in Quanterix common stock. Uman is widely known to possess the leading antibodies available measure neurofilament light (Nf-L) and provider of choice for biopharmaceutical and diagnostic applications. Quanterix is the digitizing biomarker analysis firm with having goal of advancing the science of precision health. Nf-L to enhance the development of therapeutics and diagnostics for neurodegenerative conditions, the acquisition will help company to achieve expertise in the brain sector.
Increasing prevalence of brain diseases is driving the growth of brain biological market. For instance, according to WHO report published in 2018, more than 300 million people ae diagnosed with clinical depression across the world. Furthermore, unavailability of efficient diagnostics in developing and undeveloped countries increasing the mortality rate of neurological disorders. For instance, as per the École des Neurosciences de Paris Île-de-France (ENP), around 6 million people die because of stroke each year, among them around 80% belong to middle- and low-income countries. These factors creating the demand of research in brain biomarker and expected to boost the growth of market over the forecast period. On the other flip, high costs involved in biomarker validation are the major roadblocks for companies and factors like the inherent variability in biomarker levels may restrain the growth of market. Nevertheless, increasing expenditure may create lucrative growth opportunity for the biomarkers market. For instance, as per the report of World Bank, the global healthcare spending increased at a CAGR of 7.45% from 2003 to 2012.
North America is dominating the brain biomarker market followed by Europe due to increasing spend on R&D and growing use of biomarkers in personalized medicine and drug discovery and development sectors. Moreover, the key players, well-established pharmaceuticals sector dominates the biomarkers market due to the rising demand of the aging population for the diagnosis and treatment of age-related diseases. For instance, as per the report every year around 1.2 million people are diagnosed neurological disorders in the USA. In addition, the greater adoption rate of biomarkers for disease diagnostics is driving the growth of the biomarkers market in North America region.
Asia Pacific is anticipated to grow at a highest CAGR over forecast period due to emerging economies and positive trends associated with research and development. Additionally, increase in disposable income, improvement in healthcare infrastructure and rise in consumer awareness for the personalized medicine are likely to contribute to the regional growth rate, factors like this will bolster the market growth over the forecast period.
Key Benefits for Brain Biomarker Market Reports –
Global Market report covers in depth historical and forecast analysis.
Global Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global Market report helps to identify opportunities in market place.
Global Market report covers extensive analysis of emerging trends and competitive landscape.
By Type - Genomic, Proteomic, Metabolomic, Imaging, Others
By Application - Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, Others
By End-use - Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations, Other
Regional & Country Analysis
North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa
Interested in this report?
Brain Biomarker Market Size By Type (Genomic, Proteomic, Metabolomic, Imaging, Others), By Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, Others) Forecast 2021-2027